Alloy Therapeutics is a biotechnology ecosystem company democratizing access to tools, technologies, and services for discovering and developing therapeutic biologics across six modalities, including antibodies, TCRs, genetic medicines, peptides, cell therapy, and drug delivery.
Alloy Therapeutics supports the scientific community through our capabilities in antibody drug discovery (monoclonal, bi/multi-specific, TCR mimics), protein engineering, high-throughput Ab expression and characterization, functional assay development, and TCR/CAR engineering.
Alloy empowers the global scientific community with broad, non-exclusive access to foundational drug discovery and development technologies and capabilities.
Alloy will never have its own drug pipeline. We reinvest 100% of our revenue back into innovation and access to innovation so that our partners may leverage the full potential of Alloy‘s platforms, services, and company creation capabilities.